{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-026303","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.975938+00:00","generated_at":"2026-06-05T19:33:22.727215+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rhythm Pharma Q4 IMCIVREE rev $24.2M; reports material weakness in IT controls","bullets":["Q4 2023 net product revenue $24.2M (FY2023 $77.4M) vs $8.8M Q4 2022; net loss $41.6M ($0.70/share).","Cash $275.8M at Dec 31, 2023; 2024 non-GAAP op expense guidance $250-270M.","Material weakness in IT general controls over user access and program change management expected in 10-K.","Completed enrollment in Phase 3 hypothalamic obesity trial (N=120); top-line data 1H2025.","Entered global licensing deal for oral MC4R agonist LB54640; IND accepted for RM-718."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-026303","json":"https://secwatch.observer/filing/0001104659-24-026303.json","markdown":"https://secwatch.observer/filing/0001104659-24-026303.md","text":"https://secwatch.observer/filing/0001104659-24-026303.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465924026303/0001104659-24-026303-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465924026303/tm246832d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:33:22.727215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d50ad01b6fbc7e73de297274120bc3be4f24787","claim":"RHYTHM PHARMACEUTICALS, INC. reported fourth quarter and full year ended December 31, 2023 results: revenue $24.2 million.","evidence_excerpt":"Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update -- Fourth quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $24.2 million -- -- Enrollment completed in 120-patient, pivotal cohort of Phase 3 setmelanotide trial in hypothalamic obesity; top-line data on track for 1H2025 -- -- Announced Phase 3","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465924026303/0001104659-24-026303-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$24.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}